Periodic and Aperiodic Components of Subthalamic Nucleus Activity Reflect Different Aspects of Motor Impairment in Parkinson's Disease.

Excessive beta oscillations in the subthalamic nucleus are established as a primary electrophysiological biomarker for motor impairment in Parkinson's disease and are currently used as feedback signals in adaptive deep brain stimulation systems. However, there is still a need for optimization of stimulation parameters and the identification of optimal biomarkers that can accommodate varying patient conditions, such as ON and OFF levodopa medication. The precise boundaries of 'pathological' oscillatory ranges, associated with different aspects of motor impairment, are still not fully clarified.

Neuronal activity features of the subthalamic nucleus associated with optimal deep brain stimulation electrode insertion path in Parkinson's disease.

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a standard treatment for advanced Parkinson's disease (PD). The precise positioning of the electrode can significantly influence the results of DBS and the overall improvement in the quality of life for PD patients receiving this therapy. We hypothesize that single unit activity (SUA) features can serve as a valid marker of the optimal DBS-electrode insertion trajectory, leading to the most favorable outcome of STN-DBS surgery.

Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment.

Analysis of serial liquid biopsy (LB) samples has been found to be a promising approach for the monitoring of tumor dynamics in the course of therapy for patients with colorectal cancer (CRC). Currently, somatic mutations are used for tracing the dynamics of the tumor via LB. However, the analysis of the dynamic changes in the molecular signatures such as microsatellite instability (MSI) is not currently used.

Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance.

Background: The widespread use of next-generation sequencing in clinical practice has contributed to the accumulation of a large number of genomic findings associated with targeted therapy; therefore, the problem of ranking the detected findings has become acute. The European Society for Medical Oncology Scale of Clinical Actionability of molecular Targets (ESCAT) system was designed by the European Society for Medical Oncology to rank biomarkers into levels of evidence that reflect their potency and clinical significance based on published clinical data. However, the ESCAT system remains imperfect, as it is based on a subjective assessment of the levels of evidence.

Secondary structure analysis of proteins within the same topology group.

The native conformation of a protein plays a decisive role in ensuring its functionality. It is established that the spatial structure of proteins may exhibit a greater degree of conservation than the corresponding amino acid sequences. This study aims to clarify structural distinctions between homologous and non-homologous proteins with identical topology.